BIO-RAD'S BIOPLEX 2200 RECEIVES FDA CLEARANCE

Bio-Rad, a multinational manufacturer and distributor of life science research products and clinical diagnostics, has received marketing clearance from the FDA for its BioPlex 2200 system, a new immunoassay platform that employs multiplexing technology to analyze for multiple disease states from single patient samples. It is the first clinical diagnostics platform to offer multiplexing technology on a fully-automated, fully-integrated random access platform.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/01-03-2005/0002762047&EDATE=)